MCO Insider Notice: 415 Common Shares Routed to Fidelity, Sale Date 09/15/2025
Rhea-AI Filing Summary
Form 144 filed for Moody's Corporation (MCO): The notice records a proposed sale of 415 common shares through Fidelity Brokerage Services LLC with an aggregate market value of $212,749.75, and an approximate sale date of 09/15/2025 on the NYSE. The filer reports acquiring those 415 shares through a combination of restricted stock vesting (134 shares on 03/01/2024) and option-related transactions recorded for 09/15/2025 (56, 134 and 91 shares), with payment shown as compensation or cash. The filing also lists six prior sales during the past three months by the same seller, each of 415 shares with gross proceeds ranging from $197,818.05 to $216,401.75. The issuer's total shares outstanding are reported as 179,400,000.
Positive
- Brokerage disclosure: Proposed sale routed through Fidelity Brokerage Services LLC, providing a clear execution venue
- Full acquisition trace: Acquisition dates and transaction types (restricted vesting and specific option grants) are itemized for the 415 shares
- Prior sales disclosed: Six prior sales in the past three months are listed with gross proceeds, supporting transparency
Negative
- None.
Insights
TL;DR: Routine insider sale of 415 shares via brokerage; not materially large relative to outstanding shares.
This Form 144 documents a planned sale of 415 common shares valued at $212,749.75, executed through a major broker. The shares were acquired through standard compensation mechanisms (restricted stock vesting and option exercises). The filing includes a sequence of prior small sales by the same individual over recent months, which suggests a programmatic disposition pattern rather than a single large liquidation. On the numbers provided, 415 shares are immaterial versus the reported 179.4 million shares outstanding, so the filing alone is unlikely to move valuation metrics.
TL;DR: Disclosure appears complete for Rule 144 requirements; broker and acquisition details are documented.
The filing supplies required broker information, acquisition dates and nature (restricted vesting and option grants), and past three-month sales, enabling standard compliance review. The signer represents no undisclosed material adverse information. The record lacks an explicit "Date of Notice" entry in the provided text, but otherwise contains the core transaction and historical sale details needed for regulatory transparency.